Early experience of seven hepatocellular carcinoma cases treated with regorafenib

Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Case Rep
Main Authors: Uchikawa, Shinsuke, Kawaoka, Tomokazu, Aikata, Hiroshi, Kodama, Kenichiro, Inagaki, Yuki, Hatooka, Masahiro, Morio, Kei, Nakahara, Takashi, Murakami, Eisuke, Hiramatsu, Akira, Tsuge, Masataka, Imamura, Michio, Kawakami, Yoshiiku, Chayama, Kazuaki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6230610/
https://ncbi.nlm.nih.gov/pubmed/30455925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1791
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados